Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number** 14D2153895	**(X3) Date Survey Completed** 07/01/2022
Name of Provider or Supplier Midwest Institute For Minimally Invasive Therapies	**Street Address, City, State** 2415 S Michigan Ave, Chicago, IL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	**Summary Statement of Deficiencies**
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the CASPER Report 0155D and interview with a College of American Pathologists (CAP) representative the laboratory failed to successfully participate in proficiency testing (PT) for the hematology analyte prothrombin time during events one and two of 2022 resulting in the initial unsuccessful performance for prothrombin time. See D2130.
D2130	HEMATOLOGY CFR(s): 493.851(f)

	Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CASPER Report 0155D and interview with a College of American Pathologists (CAP) representative the laboratory failed to successfully participate in proficiency testing (PT) for the hematology analyte prothrombin time during events one and two of 2022, resulting in the initial unsuccessful performance for prothrombin time. Findings include: 1. Review of the CASPER Report 0155D revealed that the initial unsuccessful PT performance occurred during CAP PT events one and two of 2022, as listed below. Hematology EVENT -1, 2022 - Prothrombin Time - 40% Unsatisfactory EVENT -2, 2022 - Prothrombin Time - 60% Unsatisfactory 2. A phone interview with the CAP PT representative on 7-1-2022 at 11:15 am confirmed the initial unsuccessful PT performance for the analyte prothrombin time for events one and two of 2022.